John J.V. McMurray et al. JCHF 2018;6:8-17

Slides:

Advertisements

Similar presentations

Clinical Outcomes with Newer Antihyperglycemic Agents

Advertisements

Study Design Scirica BM, Bhatt DL Braunwald et al, Sexagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

R2. 하효정 / 이상열 교수님 NEJM Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

The Evolution of Cardiovascular Outcomes Trials in T2DM Over the Years

LEADER trial: Primary Outcome

Disclosure Consultations and Honoraria Grant Support

Adherence to and persistence with oral antidiabetic medication were evaluated in a sample of 238,372 patients with type 2 diabetes initiating a dipeptidyl.

SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.

Diabetes and Risk of CV Outcomes

Figure 6 Differences in glycaemic control with the study drug

Global Projections for Diabetes:

Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Robert W. Yeh et al. JACC 2017;70:

T2DM and CV Outcomes Trials: A Deep Dive!

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

EXAMINE Study: Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome.

Dean J. Kereiakes et al. JACC 2017;70:

Carolyn Y. Ho et al. JCHF 2015;3:

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

Antihyperglycemic Therapy

Caroline Zotter-Tufaro et al. JCHF 2015;3:

Belinda Gray et al. JCHF 2013;1:

John E. Sanderson JCHF 2014;2:93-94

David F. Katz et al. JACEP 2016;j.jacep

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

Prakash Harikrishnan et al. JACEP 2015;1:

Wayne L. Miller et al. JCHF 2013;1:

Rachel Bastiaenen et al. JACEP 2016;2:

Jordan B. King et al. JCHF 2016;4:

G. Michael Felker et al. JCHF 2014;2:

APD Restitution and Ventricular Arrhythmia Inducibility (A to D) Examples of dynamic APD restitution curves at remote (A and C) and peri-infarcted (B and.

David F. Katz et al. JACEP 2017;3:20-28

Connie W. Tsao et al. JCHF 2016;4:

Rami Doukky et al. JCHF 2016;4:24-35

Jennifer T. Thibodeau et al. JCHF 2014;2:24-31

Neal A. Chatterjee et al. JCHF 2014;2:

Takumi Higuma et al. JCIN 2016;9:

Gordon R. Reeves et al. JCHF 2017;j.jchf

Peter E. Carson et al. JCHF 2015;3:

Maria R. Costanzo et al. JCHF 2016;4:

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

John Rickard et al. JCHF 2013;1:

Jacqueline Baras Shreibati et al. JCHF 2017;j.jchf

Completed and ongoing CVOTs (6–14,39,44–58)

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Glucose-lowering medication in type 2 diabetes: overall approach.

Connie W. Tsao et al. JCHF 2016;4:

John A. Sallach et al. JIMG 2009;2:

Leslee J. Shaw et al. JIMG 2010;3:

Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and.

Christian Madelaire et al. JCHF 2018;6:

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Constantijn Franssen et al. JCHF 2016;4:

Dennis M. McNamara et al. JCHF 2014;2:

Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.

Orly Vardeny et al. JCHF 2016;4:

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Maria R. Costanzo et al. JCHF 2016;4:

Gianluigi Savarese et al. JCHF 2016;4:

Patient disposition and study protocol.

Glucose-lowering medication in type 2 diabetes: overall approach.

Constantijn Franssen et al. JCHF 2016;4:

Presentation transcript:

John J.V. McMurray et al. JCHF 2018;6:8-17 Study Timeline DPP = dipeptidyl peptidase; EXAMINE = Examination of Cardiovascular Outcomes With Alogliptin vs Standard of Care; SAVOR-TIMI 53 = Saxagliptin Assessment of Vascular Outcomes Recorded in Patients With Diabetes Mellitus-Thrombolysis In Myocardial Infarction 53; TECOS = Trial Evaluating Cardiovascular Outcomes With Sitagliptin; VIVIDD = Vildagliptin in Ventricular Dysfunction Diabetes trial. John J.V. McMurray et al. JCHF 2018;6:8-17 2018 American College of Cardiology Foundation